2. Metabolic Enzyme/Protease Vitamin D Related/Nuclear Receptor Epigenetics Cell Cycle/DNA Damage Apoptosis NF-κB Immunology/Inflammation
  3. Endogenous Metabolite Estrogen Receptor/ERR Sirtuin MDM-2/p53 PDI Ferroptosis Reactive Oxygen Species (ROS)
  4. 4-Hydroxyestrone

4-Hydroxyestrone (4-OHE1) is a brain-penetrant estrogen metabolite. 4-Hydroxyestrone shows neuroprotective effects involving increased cytoplasmic localization of p53 resulting from SIRT1-mediated p53 deacetylation. 4-Hydroxyestrone relies on PDI to mediate its protective effect against chemically induced ferroptosis in estrogen receptor-negative cancer cells. 4-Hydroxyestrone inhibits lipid peroxidation and lipid-ROS accumulation. 4-Hydroxyestrone blocks preovulatory luteinizing hormone surges in Rattus norvegicus. 4-Hydroxyestrone can be used for the researches of neurodegeneration, breast cancer and endocrine disease.

For research use only. We do not sell to patients.

4-Hydroxyestrone

4-Hydroxyestrone Chemical Structure

CAS No. : 3131-23-5

Size Price Stock Quantity
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of 4-Hydroxyestrone:

4-Hydroxyestrone Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE 4-Hydroxyestrone

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms
Human Endogenous Metabolite Microbial Metabolite

View All Estrogen Receptor/ERR Isoform Specific Products:

View All Isoforms
Estrogen receptor ERα ERβ ERRα ERRβ ERRγ

View All Sirtuin Isoform Specific Products:

View All Isoforms
Sirtuin SIRT1 SIRT2 SIRT3 SIRT6 SIRT5 SIRT7 SIRT4

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

4-Hydroxyestrone (4-OHE1) is a brain-penetrant estrogen metabolite. 4-Hydroxyestrone shows neuroprotective effects involving increased cytoplasmic localization of p53 resulting from SIRT1-mediated p53 deacetylation. 4-Hydroxyestrone relies on PDI to mediate its protective effect against chemically induced ferroptosis in estrogen receptor-negative cancer cells. 4-Hydroxyestrone inhibits lipid peroxidation and lipid-ROS accumulation. 4-Hydroxyestrone blocks preovulatory luteinizing hormone surges in Rattus norvegicus. 4-Hydroxyestrone can be used for the researches of neurodegeneration, breast cancer and endocrine disease[1][2][3].

IC50 & Target[1]

SIRT1

 

In Vitro

4-Hydroxyestrone (2.5-10 μM; 24 h) strongly protects HT22 immortalized mouse hippocampal neuronal cells against glutamate-induced oxidative cell death[1].
4-Hydroxyestrone (5 μM; 4-24 h) induces cytoplasmic translocation of p-p53(Ser15) in HT22 immortalized mouse hippocampal neuronal cells treated with 5 mM glutamate, reversing glutamate-induced nuclear accumulation of p-p53(Ser15) over 4-24 hours[1].
4-Hydroxyestrone (5 μM; 4-24 h) promotes cytoplasmic accumulation of p-MDM2(Ser166) in HT22 immortalized mouse hippocampal neuronal cells treated with 5 mM glutamate, reversing glutamate-induced nuclear accumulation of p-MDM2(Ser166) over 4-24 hours[1].
4-Hydroxyestrone (5 μM; 24 h) inhibits glutamate-induced p53 transcriptional activity in HT22 immortalized mouse hippocampal neuronal cells by reducing GADD45α mRNA and protein levels, correlating with improved cell viability after 24-hour co-incubation[1].
4-Hydroxyestrone (5 μM) maintains SIRT1 protein levels and function in HT22 immortalized mouse hippocampal neuronal cells treated with 5 mM glutamate, mediating p53 deacetylation and cytoplasmic translocation to exert neuroprotection[1].
4-Hydroxyestrone (0.5-8 μM; 12-24 h) strongly protects estrogen receptor-negative MDA-MB-231 human breast cancer cells from Erastin (HY-15763)-induced ferroptotic cell death in a concentration-dependent manner[2].
4-Hydroxyestrone (1-8 μM; 24 h) strongly protects estrogen receptor-negative HCC1937 human breast cancer cells from Erastin + BSO (HY-106376)-induced ferroptotic cell death in a concentration-dependent manner[2].
4-Hydroxyestrone (4-8 μM; 12 h) abrogates Erastin-induced lipid peroxidation and lipid-ROS accumulation in estrogen receptor-negative MDA-MB-231 and HCC1937 human breast cancer cells[2].
4-Hydroxyestrone (0.0625-64 μM; 3 h) binds to PDI in live MDA-MB-231 human breast cancer cells, stabilizing the protein against thermal denaturation in a concentration-dependent manner[2].
4-Hydroxyestrone (10 μM) directly inhibits the catalytic activity of wild-type human PDI, but not PDIH256A mutant[2].
4-Hydroxyestrone (8 μM; 12 h) inhibits Erastin-induced iNOS dimerization and subsequent NO accumulation in estrogen receptor-negative MDA-MB-231 human breast cancer cells[2].
4-Hydroxyestrone (4-8 μM; 24 h) relies on PDI to mediate its protective effect against chemically induced ferroptosis in estrogen receptor-negative MDA-MB-231 and HCC1937 human breast cancer cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

4-Hydroxyestrone Related Antibodies

Cell Viability Assay[1]

Cell Line: HT22 immortalized mouse hippocampal neuronal cells
Concentration: 2.5 μM, 5 μM, 10 μM
Incubation Time: 24 h
Result: Exhibited the strongest neuroprotective effect against glutamate-induced oxidative cell death among 25 tested estrogen metabolites, with a significantly greater protective effect than its parent hormone estrone.
Increased cell viability to ~60% of control at 2.5 μM, ~85% of control at 5 μM, and ~70% of control at 10 μM compared to glutamate-only treatment.
Almost completely abrogated glutamate-induced cell death as confirmed by flow cytometry with PI and annexin-V staining, with no alteration to the cell cycle.

Western Blot Analysis[1]

Cell Line: HT22 immortalized mouse hippocampal neuronal cells
Concentration: 5 μM
Incubation Time: 4 h, 8 h, 12 h, 24 h
Result: Reversed glutamate-induced time-dependent increase in nuclear p-p53(Ser15) levels and decrease in cytosolic p-p53(Ser15) levels.
Increased cytosolic p-p53(Ser15) levels over time, while decreasing nuclear p-p53(Ser15) levels, with only <10% of cells showing nuclear p-p53(Ser15) staining at 24 hours.\nReversed glutamate-induced trend of declining cytoplasmic p-MDM2(Ser166) levels and increasing nuclear p-MDM2(Ser166) levels.
Caused a drastic increase in cytoplasmic p-MDM2(Ser166) levels at 24 hours, with almost all cells showing cytoplasmic p-MDM2(Ser166) staining, while nuclear p-MDM2(Ser166) levels remained low.

Cell Viability Assay[2]

Cell Line: HCC1937 human breast cancer cells
Concentration: 1, 2, 4, 8 μM; (HCC1937 cells with 20 μM Erastin + 40 μM BSO)
Incubation Time: 24 h
Result: Showed protective effect against erastin + BSO-induced cell death in HCC1937 cells.
In Vivo

4-Hydroxyestrone (10 µg/rat; s.c.; daily; 7 days) provides near-complete neuroprotection against Kainic acid (HY-N2309)-induced hippocampal oxidative damage and working memory impairment in male Sprague-Dawley rats[1].
4-Hydroxyestrone (100 μg; i.v.; single injection) effectively inhibits the preovulatory LH surge in 86% of 4-day cycling rats when administered at 0900 h on proestrus, but is completely ineffective when given at 1000 h or 1200 h[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague-Dawley (male, 250-270 g, Kainic acid-induced hippocampal oxidative damage)[1]
Dosage: 10 µg/rat
Administration: s.c.; daily; 7 consecutive days
Result: Afforded almost complete neuroprotection of the hippocampal CA3 region.
Markedly reduced degenerating neurons (Fluoro-Jade B-positive) and TUNEL-positive apoptotic cells compared to rats treated with kainic acid alone.
Strongly prevented kainic acid-induced reduction in working memory, with protective effect markedly stronger than that of 17β-estradiol (HY-B0141) at the same dose.
Animal Model: Sprague-Dawley CD rats (adult female virgin, 250-300 g BW, consistent 4-day estrous cycles)[3]
Dosage: 100 μg (0900 h administration); 100 μg (1000 h administration); 100 μg (1200 h administration)
Administration: i.v.; single injection
Result: Abolished the preovulatory LH surge in 6 of 7 rats, with a cumulative plasma LH concentration of 182 ng/mL between 1400-2000 h when administered at 0900 h.
Showed no effect on the LH surge, with 0 of 5 rats showing suppression at 1000 h or 1200 h; cumulative plasma LH levels were 1775 ng/mL (1000 h) and 1416 ng/mL (1200 h), not significantly different from vehicle controls.
Molecular Weight

286.37

Formula

C18H22O3
CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

OC(C=C1)=C(O)C(CC[C@@]2([H])[C@]3([H])CC4)=C1[C@@]2([H])CC[C@]3(C)C4=O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

Methanol : ≥ 10 mg/mL (34.92 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.4920 mL 17.4599 mL 34.9199 mL
5 mM 0.6984 mL 3.4920 mL 6.9840 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation

Purity: ≥99.0%

SDS (396 KB)

COA (253 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
Methanol 1 mM 3.4920 mL 17.4599 mL 34.9199 mL 87.2996 mL
5 mM 0.6984 mL 3.4920 mL 6.9840 mL 17.4599 mL
10 mM 0.3492 mL 1.7460 mL 3.4920 mL 8.7300 mL
15 mM 0.2328 mL 1.1640 mL 2.3280 mL 5.8200 mL
20 mM 0.1746 mL 0.8730 mL 1.7460 mL 4.3650 mL
25 mM 0.1397 mL 0.6984 mL 1.3968 mL 3.4920 mL
30 mM 0.1164 mL 0.5820 mL 1.1640 mL 2.9100 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

4-Hydroxyestrone Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

4-Hydroxyestrone3131-23-54-OHE1Endogenous MetaboliteEstrogen Receptor/ERRSirtuinMDM-2/p53PDIFerroptosisReactive Oxygen Species (ROS)Protein Disulfide Isomerasesinducible nitric oxide synthase (iNOS)protein disulfide isomerase (PDI)SIRT1Sprague-Dawley ratsHT22 immortalized mouse hippocampal neuronal cellsMDA-MB-231 human breast cancer cellsp53oxidative neuronal damageHCC1937 human breast cancer cellsferroptotic cell deathInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
4-Hydroxyestrone
Cat. No.:
HY-W009300
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (396 KB) Français - FR (396 KB) Deutsch - DE (396 KB) Norwegian - NO (396 KB) Español - ES (396 KB) Swedish - SV (396 KB) Italian - IT (396 KB) Korean - KR (396 KB) Portuguese - PT (396 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.